BACKGROUND: The blood of cancer patients is known to contain fragments of RNA released from the tumor. The application of genomic profiling techniques to plasma RNA may allow the unbiased selection of cancer markers in the blood, but the informative value of genomic profiling of plasma RNA is currently unknown. METHODS: We used cDNA microarray hybridization to perform genomic profiling of plasma RNA from colorectal cancer (CRC) patients and from healthy donors. From a list of 40 genes differentially upregulated in cancer patients, we randomly selected 4 genes for further characterization. These 4 markers were analyzed by quantitative reverse-transcription PCR in a wide set of samples including paired samples from the same CRC patients before and after surgical resection of the tumor. RESULTS: Three of the selected markers - EPAS1, UBE2D3, and KIAA0101 - were confirmed by PCR to be significantly increased in cancer compared to healthy donors. Importantly, 2 of the markers, EPAS1 and UBE2D3, showed a significant decrease after surgery, returning to the levels of healthy donors. Finally, supervised class prediction using these 3 markers correctly (77%) assigned presurgery samples to the CRC group and assigned postsurgery samples from the same patients to the healthy group. CONCLUSIONS: Our findings demonstrate the usefulness of gene expression profiling of circulating plasma RNA to find cancer markers of potential clinical value.
BACKGROUND: The blood of cancerpatients is known to contain fragments of RNA released from the tumor. The application of genomic profiling techniques to plasma RNA may allow the unbiased selection of cancer markers in the blood, but the informative value of genomic profiling of plasma RNA is currently unknown. METHODS: We used cDNA microarray hybridization to perform genomic profiling of plasma RNA from colorectal cancer (CRC) patients and from healthy donors. From a list of 40 genes differentially upregulated in cancerpatients, we randomly selected 4 genes for further characterization. These 4 markers were analyzed by quantitative reverse-transcription PCR in a wide set of samples including paired samples from the same CRCpatients before and after surgical resection of the tumor. RESULTS: Three of the selected markers - EPAS1, UBE2D3, and KIAA0101 - were confirmed by PCR to be significantly increased in cancer compared to healthy donors. Importantly, 2 of the markers, EPAS1 and UBE2D3, showed a significant decrease after surgery, returning to the levels of healthy donors. Finally, supervised class prediction using these 3 markers correctly (77%) assigned presurgery samples to the CRC group and assigned postsurgery samples from the same patients to the healthy group. CONCLUSIONS: Our findings demonstrate the usefulness of gene expression profiling of circulating plasma RNA to find cancer markers of potential clinical value.
Authors: Zeina Kais; Sanford H Barsky; Haritha Mathsyaraja; Alicia Zha; Derek J R Ransburgh; Gang He; Robert T Pilarski; Charles L Shapiro; Kun Huang; Jeffrey D Parvin Journal: Mol Cancer Res Date: 2011-06-14 Impact factor: 5.852
Authors: N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla Journal: Oncol Lett Date: 2011-04-28 Impact factor: 2.967
Authors: Joan M Hevel; Laura C Olson-Buelow; Balasubramanian Ganesan; John R Stevens; Jared P Hardman; Ann E Aust Journal: BMC Genomics Date: 2008-08-07 Impact factor: 3.969
Authors: Vardit Moshayoff; Ouriel Faktor; Luigi Laghi; Giuseppe Celesti; Tamar Peretz; Dan Keret; Dana Cohen; Eran Israeli Journal: PLoS One Date: 2016-07-21 Impact factor: 3.240